Related Experiment Video
Updated: Apr 28, 2026
A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
Published on: May 12, 2023
[Treating chronic persistent bronchial asthma children with abnormal myocardial enzyme spectrum by Yupingfeng powder:
Insights
Yupingfeng Powder (YP) combined with routine therapy improved clinical symptoms and myocardial enzyme spectrum in children with chronic persistent bronchial asthma (CPBA). This treatment enhanced immunity and asthma control test (C-ACT) scores.
Area of Science:
- Pediatrics
- Immunology
- Pulmonology
Background:
- Chronic persistent bronchial asthma (CPBA) in children can be associated with abnormal myocardial enzyme spectrum (AMES).
- Standard treatments for CPBA may not fully address all associated physiological changes.
- Investigating complementary therapies for CPBA is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the clinical efficacy of Yupingfeng Powder (YP) combined with routine therapy for CPBA children presenting with AMES.
- To assess the impact of YP on clinical symptoms, pulmonary function, and myocardial enzyme levels in pediatric asthma patients.
Main Methods:
- A randomized controlled trial involving 156 CPBA children with AMES from January 2010 to December 2012.
- Patients received routine treatment (inhaled corticosteroids and/or leukotriene regulators); the treatment group also received YP for 3 months.
- Evaluated Children's Asthma Control Test (C-ACT) scores, pulmonary function (FEV1%, PEF%), and myocardial enzyme spectrum (CK-MB, CK, LDH, AST) pre- and post-treatment.
Main Results:
- The YP group showed significant improvements in C-ACT scores, FEV1%, and PEF% compared to the control group post-treatment.
- Myocardial enzyme levels (CK-MB, CK, LDH) decreased significantly in the YP group after treatment and at 3-month follow-up.
- YP treatment led to a significant reduction in myocardial enzyme levels and improvement in asthma control metrics compared to routine therapy alone.
Conclusions:
- Yupingfeng Powder (YP) demonstrates clinical efficacy in treating CPBA children with AMES when used adjunctively with routine therapy.
- YP appears to enhance both specific and non-specific immunity, leading to improved clinical symptoms and normalized myocardial enzyme spectrum.
- The findings suggest YP is a beneficial addition to the management of pediatric asthma with associated myocardial enzyme abnormalities.
Objective:
To observe the clinical efficacy of treating chronic persistent bronchial asthma (CPBA) children with abnormal myocardial enzyme spectrum (AMES) by Yupingfeng Powder (YP) combined routine therapy.
Methods:
From January 2010 to December 2012, 156 CPBA children patients with AMES were randomly assigned to the treatment group (80 cases) and the control group (76 cases). All patients received routine treatment (inhaled corticosteroids and/or leukotriene regulator). Besides, those in the treatment group took YP. The treatment duration was 3 months. The scores of children asthma control test (C-ACT), pulmonary function (FEV,% and PEF%), myocardial enzyme spectrum were observed before and after treatment, and 3 months before and after treatment. The myocardial enzyme spectrum of 40 healthy children at the baby clinics during the same period were recruited as the control.
Results:
Compared with the control group, creatine kinase isoenzyme (CK-MB), creatine kinase(CK), and lactate dehydrogenase (LDH) increased in the two treatment groups (P <0.01), but there was no statistical difference in AST (P >0.05). Compared with before treatment in the same group, CK-MB, CK, LDH, and AST decreased in the treatment group after treatment and 3 months after treatment (P <0.01). CK-MB, CK, LDH, and AST decreased in the control group 3 months after treatment (P <0.01, P <0.05).Compared with after treatment, CK decreased in the control group 3 months after treatment (P <0.01). C-ACT score, FEV(1),%, and PEF% all increased in the two groups after treatment and 3 months after treatment (P <0.01, P <0.05). Compared with after treatment in the same group, CK decreased in the control group 3 months after treatment (P <0. 01). Compared with the control group in the same period, post-treatment CK-MB and CK decreased (P <0. 01, P <0. 05), while post-treatment C-ACT score, FEV, %, and PEF% increased (P <0.05) in the treatment group (P <0.05).
Conclusion:
YP could strengthen specific and non-specific immunity of the organism, and improve clinical symptoms and the level of myocardial enzyme spectrum.
Related Concept Videos
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.